<DOC>
	<DOCNO>NCT02072720</DOCNO>
	<brief_summary>The main question study VEGF ( vascular endothelial growth factor ) expression tumor upregulated chemoradiation bevacizumab inhibits subsequent vessel growth tumor . - Therefore first aim study identify time point induction VEGF tumor tissue esophagus carcinoma chemoradiation ( 1,2,3 4 week chemoradiation ) . - If identify increase expression VEGF certain time point , second aim determine inhibit subsequent tumor vessel growth administration bevacizumab .</brief_summary>
	<brief_title>Angiogenic Factor Expression During Fractionated Irradiation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Angiogenesis Inducing Agents</mesh_term>
	<criteria>patient receive chemoradiation follow CROSSschedule surgery esophageal carcinoma ability give inform consent age 18 year old pregnancy evidence bleed diathesis , coagulopathy inflammation GItract brain metastasis diastolic/ systolic hypertension , respond treatment arterial thromboembolism medical history surgery within month prior start bevacizumab treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Radiotherapy</keyword>
	<keyword>VEGF</keyword>
	<keyword>esophagus carcinoma</keyword>
	<keyword>bevacizumab</keyword>
</DOC>